Weigao Blood announced that it plans to purchase 100% of Purui Pharmaceutical's shares by issuing shares at a transaction price of 8.511 billion yuan. As of December 31, 2024, the total assets and net assets of the target company were 8.511 billion yuan, 8.511 billion yuan, and revenue for 2024 was 1,673 billion yuan; total assets and net assets of the listed company were 6.99 billion yuan and 5.597 billion yuan respectively, and revenue of the 2024 fiscal year was 3.64 billion yuan. This transaction constituted a major asset restructuring and related transaction, but it did not constitute a restructuring and listing, since all parties to the transaction were controlled by the actual controller Chen Xueli, and the actual controller did not change before and after the transaction.

Weigao Blood announced that it plans to purchase 100% of Purui Pharmaceutical's shares by issuing shares at a transaction price of 8.511 billion yuan. As of December 31, 2024, the total assets and net assets of the target company were 8.511 billion yuan, 8.511 billion yuan, and revenue for 2024 was 1,673 billion yuan; total assets and net assets of the listed company were 6.99 billion yuan and 5.597 billion yuan respectively, and revenue of the 2024 fiscal year was 3.64 billion yuan. This transaction constituted a major asset restructuring and related transaction, but it did not constitute a restructuring and listing, since all parties to the transaction were controlled by the actual controller Chen Xueli, and the actual controller did not change before and after the transaction.